Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.
Press releases published on May 5, 2025
Rose Hill Life Sciences Appoints Biopharma Veteran Jama Pitman as Strategic Advisor
GlobeNewswire
·
May 5, 2025
Seasoned pharmaceutical executive to advise on clinical development, regulatory strategy, and commercialization as Company accelerates its psilocybin-based therapeutic programs BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences (“The Company” …
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
GlobeNewswire
·
May 5, 2025
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921’s anti-inflammatory impact on the immune landscape in the …
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
GlobeNewswire
·
May 5, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial …
Cerence AI and Code Factory Collaborate to Bring Voice-Powered Interaction to Self-Service Kiosks
GlobeNewswire
·
May 5, 2025
BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced an expanded collaboration with its long-time partner and distributor, …
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 5, 2025
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate …
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
GlobeNewswire
·
May 5, 2025
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
May 5, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced …
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
GlobeNewswire
·
May 5, 2025
AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in …